Isabela de Souza Gomes

Isabela de Souza Gomes

Auto-generated profile, based on publicly available information

Isabela de Souza Gomes

Departamento de Ciência da Computação, Universidade Federal de Viçosa, Minas Gerais, Brazil

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 June 2022 in Computers in Biology and Medicine
Verified
Journal Article
Closed access
VPVinícius de Almeida Paiva
Vinícius de Almeida Paiva
IGIsabela de Souza Gomes
Isabela de Souza Gomes
CMCleiton Rodrigues Monteiro
Cleiton Rodrigues Monteiro
MMMurillo Ventura Mendonça
Murillo Ventura Mendonça
PMPedro Magalhães Martins
Pedro Magalhães Martins
SSSabrina de Azevedo Silveira
Sabrina de Azevedo Silveira

17 March 2023 in Antiviral Research
Verified
Journal Article
Closed access
JRJojo Silva Rodrigues
Jojo Silva Rodrigues
PGPoliana Aparecida Rodrigues Gazolla
Poliana Aparecida Rodrigues Gazolla
IPIago da Cruz Pereira
Iago da Cruz Pereira
RDROBERTO DIAS
ROBERTO DIAS
ISItalo Esposti Poly da Silva
Italo Esposti Poly da Silva
SPSergio De Paula
Sergio De Paula

22 April 2022 in PLOS ONE
Verified
Journal Article
Open access
PDF file
IGIsabela de Souza Gomes
Isabela de Souza Gomes
CSCharles Abreu Santana
Charles Abreu Santana
LMLeandro Soriano Marcolino
Leandro Soriano Marcolino
LLLeonardo Henrique França de Lima
Leonardo Henrique França de Lima
RMRaquel Cardoso de Melo-Minardi
Raquel Cardoso de Melo-Minardi
SSSabrina de Azevedo Silveira
Sabrina de Azevedo Silveira
The development of new drugs is a very complex and time-consuming process, and for this reason, researchers have been resorting heavily to drug repurposing techniques as an alternative for the treatment of various diseases. This approach is especially interesting when it comes to emerging diseases with high rates of infection, because the lack of a quickly cure brings many human losses until the mitigation of the epidemic, as is the case of COVID-19. In this work, we combine an in-house developed machine learning strategy with docking, MM-PBSA calculations, and metadynamics to detect potential inhibitors for SARS-COV-2 main protease among FDA approved compounds. To assess the ability of our machine learning strategy to retrieve potential compounds we calculated the Enrichment Factor of compound datasets for three well known protein targets: HIV-1 reverse transcriptase (PDB 4B3P), 5-HT2A serotonin receptor (PDB 6A94), and H1 histamine receptor (PDB 3RZE). The Enrichment Factor for each target was, respectively, 102.5, 12.4, 10.6, which are considered significant values. Regarding the identification of molecules that can potentially inhibit the main protease of SARS-COV-2, compounds output by the machine learning step went through a docking experiment against SARS-COV-2 Mpro. The best scored poses were the input for MM-PBSA calculations and metadynamics using CHARMM and AMBER force fields to predict the binding energy for each complex. Our work points out six molecules, highlighting the strong interaction obtained for Mpro-mirabegron complex. Among these six, to the best of our knowledge, ambenonium has not yet been described in the literature as a candidate inhibitor for the SARS-COV-2 main protease in its active pocket.